The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders

Annals of Clinical Psychiatry

Volumn 24, Issue 1, 2012, Pages 38-55

  Beaulieu, Serge ^a   Saury, Sybille ^a   Sareen, Jitender ^b   Tremblay, Jacques ^c   Schütz, Christian G ^d   McIntyre, Roger S ^e   Schaffer, Ayal ^f  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bipolar disorder; Comorbidity; Dual diagnosis; Major depressive disorder; Psychopharmacologic treatments; Psychosocial treatments; Substance use disorders

Indexed keywords

ALCOHOL; AMITRIPTYLINE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CANNABIS; CARBAMAZEPINE; COCAINE; DESIPRAMINE; DIAMORPHINE; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LITHIUM; METHADONE; MIRTAZAPINE; MOOD STABILIZER; NALTREXONE; NEFAZODONE; NEUROLEPTIC AGENT; OPIATE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; TRANQUILIZER;

ADD ON THERAPY; ALCOHOL ABUSE; ALCOHOLISM; ASSERTIVE COMMUNITY TREATMENT; BEHAVIOR THERAPY; BIPOLAR DISORDER; CANADA; CANNABIS ADDICTION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMMUNITY CARE; COMORBIDITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GROUP THERAPY; HAMILTON SCALE; HEROIN DEPENDENCE; HUMAN; LIVER TOXICITY; MAJOR DEPRESSION; MENTAL HEALTH CARE; META ANALYSIS (TOPIC); MOOD DISORDER; MOTIVATIONAL THERAPY; MULTIPLE DRUG ABUSE; OPIATE ADDICTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBSTANCE ABUSE; TREATMENT OUTCOME; YOUNG MANIA RATING SCALE; ADDICTION; ADVISORY COMMITTEE; METHODOLOGY;

ADVISORY COMMITTEES; ALCOHOLISM; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CANADA; COCAINE-RELATED DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; HUMANS; MOOD DISORDERS; OPIOID-RELATED DISORDERS; PSYCHOTHERAPY; SUBSTANCE-RELATED DISORDERS;

EID: 84861423058     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518.
2. Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56:730-737. (Pubitemid 39539830)
3. Bartels SJ, Blow FC, Van Citters AD, et al. Dual diagnosis among older adults: co-occurring substance abuse and psychiatric illness. J Dual Diagn. 2006;2:9-30. (Pubitemid 44392541)
4. Buckley PF. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. J Clin Psychiatry. 2006;67(suppl 7):5-9. (Pubitemid 44378993)
5. Couwenbergh C, van den Brink W, Zwart K, et al. Comorbid psychopathology in adolescents and young adults treated for substance use disorders: a review. Eur Child Adolesc Psychiatry. 2006;15:319-328. (Pubitemid 44306139)
6. Jané-Llopis E, Matytsina I. Mental health and alcohol, drugs and tobacco: a review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugs. Drug Alcohol Rev. 2006;25:515-536. (Pubitemid 44837643)
7. Thomasius R, Sack P-M, Petersen KU. DSM-IV Axis-I comorbidity among illicit drug users seeking treatment for substance use disorders: results from the Multi-centre Study of Psychiatric Comorbidity in Drug Addicts (MUPCDA). Mental Health and Substance Use. 2010;3:182-192.
8. Cerullo MA, Strakowski SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy. 2007;2:29.
9. Schaffer A, Cairney J, Veldhuizen S, et al. A population-based analysis of distinguishers of bipolar disorder from major depressive disorder. J Affect Disord. 2010;125:103-110.
10. Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl. 1996;30:17-30. (Pubitemid 26000488)
11. Goldstein BI, Bukstein OG. Comorbid substance use disorders among youth with bipolar disorder: opportunities for early identification and prevention. J Clin Psychiatry. 2010;71:348-358.
12. Kessler RC. Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. In: Tohen M, ed. Comorbidity in affective disorders. New York, NY: Marcel Dekker Inc.; 1999:1-26.
13. Strakowski SM, DelBello MP, Fleck DE, et al. Effects of co-occurring alcohol abuse on the course of bipolar disorder following a first hospitalization for mania. Arch Gen Psychiatry. 2005;62:851-858. (Pubitemid 41126879)
14. Strakowski SM, DelBello MP, Fleck DE, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry. 2007;64:57-64. (Pubitemid 46041739)
15. Swann AC. The strong relationship between bipolar and substance-use disorder. Ann N Y Acad Sci. 2010;1187:276-293.
16. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;(7 suppl 3):5-69. (Pubitemid 41065248)
17. Brady KT, Sonne SC, Malcolm RJ, et al. Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder. Exp Clin Psychopharmacol. 2002;10:276-285. (Pubitemid 34919936)
18. Campbell JL, Thomas HM, Gabrielli W, et al. Impact of desipramine or carbamazepine on patient retention in outpatient cocaine treatment: preliminary findings. J Addict Dis. 1994;13:191-199.
19. Campbell J, Nickel EJ, Penick EC, et al. Comparison of desipramine or carbamazepine to placebo for crack cocaine-dependent patients. Am J Addict. 2003;12:122-136. (Pubitemid 36583420)
20. Rubio G, López-Muñoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord. 2006;8:289-293.
21. Brown ES, Nejtek VA, Perantie DC, et al. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry. 2003;64:197-201. (Pubitemid 36268323)
22. Brown ES, Perantie DC, Dhanani N, et al. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. J Affect Disord. 2006;93:219-222. (Pubitemid 43816049)
23. Guille C, Sachs G. Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1035-1039. (Pubitemid 35256094)
24. Huguelet P, Morand-Collomb S. Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol Res. 2005;52:392-394. (Pubitemid 41534617)
25. Azorin JM, Bowden CL, Garay RP, et al. Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism. Neuropsychiatr Dis Treat. 2010;6:37-46.
26. Perugi G, Toni C, Frare F, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol. 2002;22:584-591. (Pubitemid 35416784)
27. Dorus W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA. 1989;262:1646-1652. (Pubitemid 19233519)
28. Kemp DE, Gao K, Ganocy SJ, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. J Clin Psychiatry. 2009;70:113-121.
29. Nunes EV, McGrath PJ, Wager S, et al. Lithium treatment for cocaine abusers with bipolar spectrum disorders. Am J Psychiatry. 1990;147:655-657. (Pubitemid 20153443)
30. Geller B, Cooper TB, Sun K, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry. 1998;37:171-178. (Pubitemid 28099184)
31. Brady KT, Sonne SC, Anton R, et al. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995;56:118-121.
32. Albanese MJ, Clodfelter RC Jr, Khantzian EJ. Divalproex sodium in substance abusers with mood disorder. J Clin Psychiatry. 2000;61:916-921. (Pubitemid 32058006)
33. Hertzman M. Divalproex sodium to treat concomitant substance abuse and mood disorders. J Subst Abuse Treat. 2000;18:371-372 (Pubitemid 30254361)
34. Salloum IM, Douaihy A, Cornelius JR, et al. Divalproex utility in bipolar disorder with co-occurring cocaine dependence: a pilot study. Addict Behav. 2007;32:410-415. (Pubitemid 44918222)
35. Salloum IM, Cornelius JR, Daley DC, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62:37-45. (Pubitemid 40096069)
36. Altintoprak AE, Zorlu N, Coskunol H, et al. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. Hum Psychopharmacol. 2008;23:313-319. (Pubitemid 351982668)
37. Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996;275:761-767. (Pubitemid 26087197)
38. Gonzalez G, Feingold A, Oliveto A, et al. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am J Drug Alcohol Abuse. 2003;29:497-514. (Pubitemid 37093363)
39. Kosten T, Falcioni J, Oliveto A, et al. Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. Am J Addict. 2004;13:191-201. (Pubitemid 38585699)
40. McDowell D, Nunes EV, Seracini AM, et al. Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial. Drug Alcohol Depend. 2005;80:209-221. (Pubitemid 41427635)
41. Nunes EV, McGrath PJ, Quitkin FM, et al. Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry. 1993;150:963-965. (Pubitemid 23156782)
42. McGrath PJ, Nunes EV, Stewart JW, et al. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry. 1996;53:232-240.
43. Nunes EV, McGrath PJ, Quitkin FM, et al. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend. 1995;39:185-195.
44. Nunes EV, Quitkin FM, Donovan SJ, et al. Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch Gen Psychiatry. 1998;55:153-160. (Pubitemid 28087601)
45. Kleber HD, Weissman MM, Rounsaville BJ, et al. Imipramine as treatment for depression in addicts. Arch Gen Psychiatry. 1983;40:649-653. (Pubitemid 13094932)
46. Muhonen LH, Lahti J, Sinclair D, et al. Treatment of alcohol dependence in patients with co-morbid major depressive disorder - predictors for the outcomes with memantine and escitalopram medication. Subst Abuse Treat Prev Policy. 2008;3:20.
47. Muhonen LH, Lönnqvist J, Juva K, et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 2008;69:392-399. (Pubitemid 351549391)
48. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152:391-397.
49. Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54:700-705. (Pubitemid 27344096)
50. Torrens M, Fonseca F, Mateu G, et al. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend. 2005;78:1-22. (Pubitemid 40354172)
51. Cornelius JR, Salloum IM, Cornelius MD, et al. Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. Psychopharmacol Bull. 1995;31:297-303.
52. Cornelius JR, Clark DB, Bukstein OG, et al. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. Addict Behav. 2005;30:1824-1833. (Pubitemid 41443317)
53. Cornelius JR, Bukstein OG, Birmaher B, et al. Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial. Addict Behav. 2001;26:735-739. (Pubitemid 32826211)
54. Cornelius JR, Bukstein OG, Salloum IM, et al. Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation. J Child Adolesc Psychopharmacol. 2004;14:33-38. (Pubitemid 38525951)
55. Cornelius JR, Bukstein OG, Wood DS, et al. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav. 2009;34:905-909.
56. Cornelius JR, Bukstein OG, Douaihy AB, et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend. 2010;112:39-45.
57. Cornelius JR, Salloum IM, Thase ME, et al. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol Bull. 1998;34:117-121. (Pubitemid 28176312)
58. Schmitz JM, Averill P, Stotts AL, et al. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend. 2001;63:207-214. (Pubitemid 32545407)
59. Petrakis I, Carroll KM, Nich C, et al. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend. 1998;50:221-226.
60. Brown ES, Bobadilla L, Nejtek VA, et al. Open-label nefazodone in patients with a major depressive episode and alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:681-685. (Pubitemid 36645071)
61. Hernandez-Avila CA, Modesto-Lowe V, Feinn R, et al. Nefazodone treatment of comorbid alcohol dependence and major depression. Alcohol Clin Exp Res. 2004;28:433-440. (Pubitemid 38380746)
62. Roy-Byrne PP, Pages KP, Russo JE, et al. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000;20:129-136. (Pubitemid 30202353)
63. Ciraulo DA, Knapp C, Rotrosen J, et al. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction. 2005;100(suppl 1):23-31. (Pubitemid 40363422)
64. Gual A, Balcells M, Torres M, et al. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol Alcohol. 2003;38:619-625. (Pubitemid 37455862)
65. Moak D, Anton R, Latham P, et al. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol. 2003;23:553-562. (Pubitemid 37443186)
66. Pettinati HM, Volpicelli JR, Luck G, et al. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol. 2001;21:143-153. (Pubitemid 32221051)
67. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189:124-131. (Pubitemid 44231270)
68. Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry. 1998;44:633-637. (Pubitemid 28496692)
69. Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167:668-675.
70. Carpenter KM, Brooks AC, Vosburg SK, et al. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend. 2004;74:123-134. (Pubitemid 38501686)
71. Yoon SJ, Pae CU, Kim DJ, et al. Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1196-1201.
72. Brown ES, Jeffress J, Liggin JD, et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry. 2005;66:756-760. (Pubitemid 40942423)
73. Longoria J, Brown ES, Perantie DC, et al. Quetiapine for alcohol use and craving in bipolar disorder. J Clin Psychopharmacol. 2004;24:101-102. (Pubitemid 38134178)
74. Martinotti G, Andreoli S, Di Nicola M, et al. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol. 2008;23:417-424.
75. Brown ES, Garza M, Carmody TJ. A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry. 2008;69:701-705. (Pubitemid 351838678)
76. Stedman M, Pettinati HM, Brown ES, et al. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol Clin Exp Res. 2010;34:1822-1831.
77. Nejtek VA, Avila M, Chen LA, et al. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. J Clin Psychiatry. 2008;69:1257-1266.
78. Brown ES, Nejtek VA, Perantie DC, et al. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol. 2003;23:384-388. (Pubitemid 36951181)
79. Brown ES, Nejtek VA, Perantie DC, et al. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord. 2002;4:406-411. (Pubitemid 36041471)
80. Albanese MJ, Suh JJ. Risperidone in cocaine-dependent patients with comorbid psychiatric disorders. J Psychiatr Pract. 2006;12:306-311. (Pubitemid 44439987)
81. Gerra G, Leonardi C, D'Amore A, et al. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:265-272. (Pubitemid 43288065)
82. Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol. 2007;27:498-502. (Pubitemid 47415050)
83. Larson EW, Olincy A, Rummans TA, et al. Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review. Alcohol Clin Exp Res. 1992;16:125-130.
84. Goyer PF, Brown GL, Minichiello MD, et al. Mood-altering effects of disulfiram in alcoholics. J Stud Alcohol. 1984;45:209-213. (Pubitemid 14063288)
85. Banys P. The clinical use of disulfiram (Antabuse): a review. J Psychoactive Drugs. 1988;20:243-261.
86. Pary R, Lippmann S, Tobias CR. Depression and alcoholism: clinical considerations in management. South Med J. 1988;81:1529-1533. (Pubitemid 19148235)
87. Petrakis I, Ralevski E, Nich C, et al. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol. 2007;27:160-165. (Pubitemid 46594932)
88. Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull. 2006; 32:644-654. (Pubitemid 44412852)
89. Kofoed L, Kania J, Walsh T, et al. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry. 1986;143:867-872. (Pubitemid 16090392)
90. Mueser KT, Noordsy DL, Fox L, et al. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict. 2003;12:242-252. (Pubitemid 36950973)
91. Maremmani I, Zolesi O, Aglietti M, et al. Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis. 2000;19:29-41. (Pubitemid 30659340)
92. Maxwell S, Shinderman MS. Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J Addict Dis. 2000;19:61-69.
93. Salloum IM, Cornelius JR, Thase ME, et al. Naltrexone utility in depressed alcoholics. Psychopharmacol Bull. 1998;34:111-115. (Pubitemid 28176311)
94. Oslin DW. Treatment of late-life depression complicated by alcohol dependence. Am J Geriatr Psychiatry. 2005;13:491-500.
95. Brown ES, Beard L, Dobbs L, et al. Naltrexone in patients with bipolar disorder and alcohol dependence. Depress Anxiety. 2006;23:492-495. (Pubitemid 44917670)
96. Sonne SC, Brady KT. Naltrexone for individuals with comorbid bipolar disorder and alcohol dependence. J Clin Psychopharmacol. 2000;20:114-115. (Pubitemid 30056370)
97. Brown SE, Carmody TJ, Schmitz JM, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res. 2009;33:1863-1869.
98. Parikh SV, Segal ZV, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord. 2009;117(suppl 1):S15-25.
99. Babor TF. Treatment for persons with substance use disorders: mediators, moderators, and the need for a new research approach. Int J Methods Psychiatr Res. 2008;17(suppl 1):S45-S49.
100. Drake RE, O'Neal EL, Wallach MA. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat. 2008;34:123-138. (Pubitemid 350216356)
101. Cleary M, Hunt GE, Matheson S, et al. Psychosocial treatments for people with co-occurring severe mental illness and substance misuse: systematic review. J Adv Nurs. 2009;65:238-258.
102. Baker AL, Hides L, Lubman DI. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. J Clin Psychiatry. 2010;71:247-254.
103. Cleary M, Hunt G, Matheson S, et al. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2008(1):CD001088.
104. Brooks A, Penn P. Comparing treatments for dual diagnosis: twelve-step and self-management and recovery training. Am J Drug Alcohol Abuse. 2003;29:359-383. (Pubitemid 36578421)
105. Brown S, Glasner-Edwards S, Tate S, et al. Integrated cognitive behavioral therapy versus twelve-step facilitation therapy for substance-dependent adults with depressive disorders. J Psychoactive Drugs. 2006;38:449-460. (Pubitemid 46340090)
106. Glasner-Edwards S, Tate S, McQuaid J, et al. Mechanisms of action in integrated cognitive-behavioral treatment versus twelve-step facilitation for substance-dependent adults with comorbid major depression. J Stud Alcohol Drugs. 2007;68:663-672. (Pubitemid 47437171)
107. Schmitz JM, Averill P, Sayre S, et al. Cognitive-behavioral treatment of bipolar disorder and substance abuse: a preliminary randomized study. Addict Disord Their Treat. 2002;1:17-24. (Pubitemid 351152174)
108. Weiss RD, Griffin ML, Greenfield SF, et al. Group therapy for patients with bipolar disorder and substance dependence: Results of a pilot study. J Clin Psychiatry. 2000;61:361-367. (Pubitemid 30345938)
109. Weiss RD, Griffin ML, Jaffee WB, et al. A "community-friendly" version of integrated group therapy for patients with bipolar disorder and substance dependence: a randomized controlled trial. Drug Alcohol Depend. 2009;104:212-219.
110. Weiss RD, Griffin ML, Kolodziej ME, et al. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry. 2007;164:100-107. (Pubitemid 46154787)
111. Baker A, Lewin T, Reichler H, et al. Motivational interviewing among psychiatric in-patients with substance use disorders. Acta Psychiatr Scand. 2002;106:233-240.
112. Baker A, Lewin T, Reichler H, et al. Evaluation of a motivational interview for substance use within psychiatric in-patient services. Addiction. 2002;97:1329-1337.
113. Hulse G, Tait R. Six-month outcomes associated with a brief alcohol intervention for adult in-patients with psychiatric disorders. Drug Alcohol Rev. 2002;21:105-112.
114. Bellack A, Bennett M, Gearon J, et al. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry. 2006;63:426-432.
115. Kay-Lambkin FJ, Baker AL, Lewin TJ, et al. Computer-based psychological treatment for comorbid depression and problematic alcohol and/or cannabis use: a randomized controlled trial of clinical efficacy. Addiction. 2009;104:378-388.
116. Edwards J, Elkins K, Hinton M, et al. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand. 2006;114:109-117. (Pubitemid 44034269)
117. Baker A, Bucci S, Lewin TJ, et al. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. Br J Psychiatry. 2006;188:439-448.
118. Drake R, McHugo G, Clark R, et al. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. Am J Orthopsychiatry. 1998;68:201-215. (Pubitemid 28215537)
119. McHugo GJ, Drake RE, Teague GB, et al. Fidelity to assertive community treatment and client outcomes in the New Hampshire dual disorders study. Psychiatr Serv. 1999;50:818-824. (Pubitemid 29258959)
120. Drebing CE, Van Ormer EA, Krebs C, et al. The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans. J Appl Behav Anal. 2005;38:359-372. (Pubitemid 43592186)
121. Helmus TC, Saules KK, Schoener EP, et al. Reinforcement of counseling attendance and alcohol abstinence in a community-based dual-diagnosis treatment program: a feasibility study. Psychol Addict Behav. 2003;17:249-251. (Pubitemid 37153100)
122. Ries RK, Dyck DG, Short R, et al. Outcomes of managing disability benefits among patients with substance dependence and severe mental illness. Psychiatr Serv. 2004;55:445-447. (Pubitemid 38445595)
123. Mangrum LF, Spence RT, Lopez M. Integrated versus parallel treatment of co-occurring psychiatric and substance use disorders. J Subst Abuse Treat. 2006;30:79-84. (Pubitemid 41827936)
124. Drake RE, Xie H, McHugo GJ, et al. Three-year outcomes of long-term patients with co-occurring bipolar and substance use disorders. Biol Psychiatry. 2004;56:749-756. (Pubitemid 39539832)
125. Essock SM, Mueser KT, Drake RE, et al. Comparison of ACT and standard case management for delivering integrated treatment for co-occurring disorders. Psychiatr Serv. 2006;57:185-196. (Pubitemid 43214464)
126. Mueser KT, Torrey WC, Lynde D, et al. Implementing evidence-based practices for people with severe mental illness. Behav Modif. 2003;27:387-411.
127. Gabe M. Mental health: a report of the Surgeon General. Home Care Provid. 2000;5:117.
128. Drake RE, Essock SM, Shaner A, et al. Implementing dual diagnosis services for clients with severe mental illness. Psychiatr Serv. 2001;52:469-476. (Pubitemid 32275306)